Ipsen Biopharmaceuticals, Inc. drugs
5 results
Increlex (mecasermin)
(mecasermin)Ipsen Biopharmaceuticals, Inc.
Usage: INCRELEX is indicated for treating growth failure in pediatric patients aged 2 and older with severe primary IGF-1 deficiency or growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. It is not a substitute for growth hormone in approved indications or for secondary IGF-1 deficiency.
Iqirvo (elafibranor)
(elafibranor)Ipsen Biopharmaceuticals, Inc.
Usage: IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in adults, either in combination with ursodeoxycholic acid (UDCA) for those with inadequate response or as monotherapy for those intolerant to UDCA. Approval is based on alkaline phosphatase reduction, not on survival improvement.
Onivyde (irinotecan hydrochloride)
(IRINOTECAN HYDROCHLORIDE)Ipsen Biopharmaceuticals, Inc.
Usage: ONIVYDE is indicated for adult patients with metastatic pancreatic adenocarcinoma, used in combination with oxaliplatin, fluorouracil, and leucovorin for first-line treatment, and with fluorouracil and leucovorin after progression on gemcitabine-based therapy. Not indicated as a single agent.
Sohonos (palovarotene)
(palovarotene)Ipsen Biopharmaceuticals, Inc.
Usage: SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients (8 years and older for females, 10 years and older for males) diagnosed with fibrodysplasia ossificans progressiva (FOP).
Somatuline depot (lanreotide acetate)
(lanreotide acetate)Ipsen Biopharmaceuticals, Inc.
Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly in patients unresponsive to surgery/radiotherapy, as well as for unresectable gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and for adults with carcinoid syndrome to reduce the need for short-acting somatostatin analogs.